Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery

被引:218
作者
Ho, GT [1 ]
Mowat, C
Goddard, CJR
Fennell, JM
Shah, NB
Prescott, RJ
Satsangi, J
机构
[1] Western Gen Hosp, Univ Dept Gastroenterol, Edinburgh EH4 2XU, Midlothian, Scotland
[2] Ninewells Hosp, Dundee DD1 9SY, Scotland
[3] St Johns Hosp, Livingston, Scotland
[4] Univ Edinburgh, Med Stat Unit, Edinburgh, Midlothian, Scotland
关键词
D O I
10.1111/j.1365-2036.2004.01945.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The failure rate of medical therapy in severe ulcerative colitis is high. A risk index, to aid the identification of patients of not responding at an early stage to intravenous corticosteroid therapy, would be useful to facilitate second-line treatment or surgery. Methods: We recruited 167 consecutive patients with severe ulcerative colitis between January 1995 and March 2002; and employed multiple logistic regression to analyse parameters within the first 3 days of medical therapy. We applied statistical modelling to formulate a risk score according to the likelihood of medical failure. Results: Sixty-seven (40%) patients failed to respond to medical therapy. Multiple logistic regression analysis identified mean stool frequency and colonic dilatation within the first 3 days and hypoalbuminaemia as independent predictors of outcome (P < 0.001, 0.001 and 0.002 respectively). A numerical risk score was formulated based on these variables. Patients with scores of 0-1, 2-3 and greater than or equal to4 had a medical therapy failure rate of 11%, 43% and 85% respectively. Receiver-operator characteristic analysis of this score yielded area under curve of 0.88, with a sensitivity of 85% and specificity of 75% using score greater than or equal to4 in predicting non-response. Conclusion: This risk score allows the early identification of patients with severe ulcerative colitis who would be suitable for second-line medical therapy or surgery.
引用
收藏
页码:1079 / 1087
页数:9
相关论文
共 25 条
[1]  
BAERT F, 1994, GASTROENTEROLOGY, pA648
[2]  
BUCKELL NA, 1979, LANCET, V1, P1226
[3]  
Carbonnel F, 2000, ALIMENT PHARM THERAP, V14, P273
[4]  
CHAKRAVARTY BJ, 1993, AM J GASTROENTEROL, V88, P852
[5]  
Cohen RD, 1999, INFLAMM BOWEL DIS, V5, P1
[6]  
Cohen RD, 1999, AM J GASTROENTEROL, V94, P1587
[7]   Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis [J].
Creed, TJ ;
Norman, MR ;
Probert, CSJ ;
Harvey, RF ;
Shaw, IS ;
Smithson, J ;
Anderson, J ;
Moorghen, M ;
Gupta, J ;
Shepherd, NA ;
Dayan, CM ;
Hearing, SD .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 (01) :65-75
[8]   Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis [J].
D'Haens, G ;
Lemmens, L ;
Geboes, K ;
Vandeputte, L ;
Van Acker, F ;
Mortelmans, L ;
Peeters, M ;
Vermeire, S ;
Penninckx, F ;
Nevens, F ;
Hiele, M ;
Rutgeerts, P .
GASTROENTEROLOGY, 2001, 120 (06) :1323-1329
[9]  
EDWARD FC, 2002, GUT, V44, P299
[10]  
HAWTHORNE AB, 2002, GUT, pA59